Characterisation of naturally occurring isothiocyanates as glutathione reductase inhibitors

Xia Li\textsuperscript{a,b,c}, Maowei Ni\textsuperscript{a,b,c}, Xiaoling Xu\textsuperscript{a,b,d} and Wei Chen\textsuperscript{a,b,c,e,f}

\textsuperscript{a}Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China; \textsuperscript{b}Institute of Cancer and Basic Medicine, Chinese Academy of Sciences, Hangzhou, China; \textsuperscript{c}Zhejiang Cancer Research Institute, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China; \textsuperscript{d}Department of Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China; \textsuperscript{e}Zhejiang Key Laboratory of Radiation Oncology, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China; \textsuperscript{f}Zhejiang Provincial Key Laboratory of Integrated Traditional Chinese and Western Medicine on Cancer, Hangzhou, China

ABSTRACT
Glutathione reductase (GR), an essential antioxidant enzyme against oxidative stress, has become an attractive drug target for the development of anticancer and antimalarial drugs. In this regard, we evaluated the naturally occurring isothiocyanates as promising GR inhibitors and elucidated the mechanism of action. It was found that benzyl isothiocyanate (BITC) and phenethyl isothiocyanate (PEITC) inhibited yeast GR (yGR) and human GR (hGR) in a time- and concentration-dependent manner. The \( K_i \) and \( k_{inact} \) of BITC against yGR were determined to be 259.87 \( \mu \)M and 0.0266 min\(^{-1} \), respectively. The GR inhibition occurred only in the presence of NADPH and persisted after extensive dialysis. The tandem mass spectrometric analysis revealed that Cys\textsuperscript{61} rather than Cys\textsuperscript{66} at the active site of yGR was mono-benzyl thiocarbamoylated by BITC. Inhibition of intracellular GR by BITC and PEITC in cultured cancer cells was also observed. BITC and PEITC were evaluated as competitive and irreversible inhibitors of GR.

Methods and materials

Materials

All reagents for enzyme assays, including yGR, recombinant human GR (hGR), bovine serum albumin (BSA), guanidine hydrochloride, ethylenediaminetetraacetic acid (EDTA) and reduced form of nicotinamide adenine dinucleotide phosphate (NADPH) were purchased from Sigma-Aldrich Chemical Co (St. Louis, MO, USA). HPLC grade acetonitrile and trifluoroacetic acid (TFA) were purchased from Tedia Company, Inc (Fairfield, OH, USA). Formic acid was obtained from ROE Scientific Inc (Newark, DE, USA). Foetal bovine serum (FBS), RPMI 1640 growth medium, DMEM growth medium, penicillin/streptomycin, phosphate-buffered saline (PBS) and trypsin were purchased from Gibco (Grand Island, NY, USA). The mass spectrometry grade trypsin was purchase from

CONTACT Wei Chen chenwei@zjcc.org.cn Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China

\( c \) 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Dialysis of BITC-inhibited GR to determine the irreversibility of GR inhibition

yGR (6 U/mL) was incubated at room temperature with 1 mM BITC in the presence of 0.2 mM NADPH for 2 h to achieve a ≥90% inhibition, followed by extensive dialysis in 500 ml PE buffer in a Slide-A-Lyzer dialysis cassette (Thermo Scientific) with a molecular mass cut-off of 10000 Da. Control samples were prepared in the absence of BITC. Aliquots (5 µL/sample) were withdrawn at different time intervals, and the remaining yGR activity was determined as described in the GR activity assay.

Substrate protection assay

NADPH-pretreated 1.5 U/mL yGR was incubated with 0.2 mM BITC in the presence or absence of GSSG (0.1, 0.2 and 0.4 mM) in PE buffer at room temperature for 2 h. After incubation, 20 µL of GR solution was withdrawn and the remaining GR activity was determined as described for the GR activity assay.

NADPH-dependent GR inhibition

yGR (1.5 U/mL) was incubated with 0.2 mM BITC or PEITC in the absence or presence of 0.2 mM NADPH in PE buffer at room temperature for 2 h. After incubation, 20 µL of GR solution was withdrawn and the remaining GR activity was determined as described for the GR activity assay.

Mass spectrometry analysis of BITC-treated GR

yGR samples for mass spectrometric analysis were prepared as described earlier for thioredoxin reductase mass spectrometric analysis with minor modifications. In brief, 8.0 µg reduced yGR (NADPH-treated) was treated with 0.2 mM BITC in the presence of 0.2 mM NADPH in PE buffer for 1 h at room temperature. The control sample without BITC was processed in the same way. After incubation, the remaining BITC was removed by a PD MiniTrap G-25 column (GE Healthcare Life Sciences). The GR samples were concentrated and then denatured in 6 M guanidine hydrochloride at 60 °C for 30 min. And then, the samples were digested with trypsin (1:50, w/w) in 25 mM ammonium bicarbonate solution at 37 °C for 3 h. The digested peptides were extracted and desalted by using Pierce® C18 Tips (Thermo Scientific, Rockford, IL, USA) following the manufacturer protocol. The digested peptides were eluted from the tips by using 80% (v/v) acetonitrile in water and the solvent was removed under vacuum. The samples were reconstituted in 0.1% (v/v) TFA aqueous solution. The above 200 ng digested peptides were analysed by a Q-Exactive Orbitrap high resolution mass spectrometer equipped with an Easy-nLC™ 1000 ultra-high pressure nano-HPLC system. The samples were separated on a C18 Acclaim® PepMap RSLC column (50 µm × 15 cm, 2 µm, 100 Å) (Thermofisher Scientific) coupled with a C18 Acclaim® PepMap 100 pre-column (100 mm × 2 cm, 5 µm, 100 Å) (Thermofisher Scientific), and then the eluted peptides were introduced into the mass spectrometer operating in tandem mass mode across a 60 min gradient [5% (v/v) acetonitrile/0.1% (v/v) formic acid to 40% acetonitrile/0.1% (v/v) formic acid in 40 min, 40% (v/v) acetonitrile/0.1% (v/v) formic acid to 90% (v/v) acetonitrile/0.1% (v/v) formic acid in 10 min and held at 90% (v/v) acetonitrile/0.1% (v/v) formic acid for another 10 min].
Determination of intracellular GR inhibition induced by ITCs in human cancer cells

A375 and A2780 cells were treated with different concentrations of BITC or PEITC (20, 40, 80 and 160 μM) for 2 h. Control samples were processed in parallel without ITCs treatment. After the treatment, the cells were collected by trypsinization. The cell pellets were washed twice with cold PBS and suspended in hypotonic phosphate buffer (1 mM) containing 1 mM EDTA, and homogenised over ice with an Omni homogeniser. The homogenate was centrifuged at 150,000 x g for 30 min at 4 °C. The supernatant was collected and used to determine GR activity as described above.

Statistical analysis

Data were analysed with software of GraphPad Prism. The two-tailed Student’s t-test was performed to illustrate the differences between treatment groups and untreated controls. Each experiment was implemented at least triplicate. p < 0.05 was considered as significance in all experiments. Values were expressed as mean ± SD.

Results

Inhibition of purified GRs by ITCs

Purified yGR or recombinant hGR (final 0.2 U/mL) in PE buffer containing 1 mg/mL BSA and 0.2 mM NADPH was incubated with various concentrations of BITC or PEITC (0, 20, 40, 80 and 160 μM) at room temperature for 2 h. The remaining GR activity was determined by GR assay. The results (Figure 2) showed that both of BITC and PEITC inhibited yeast or human GR in a concentration-dependent manner. BITC exerted comparable inhibitory effect against both of yeast and human GRs, but PEITC showed much better inhibitory effect against yGR than hGR. Thus, BITC and yGR were selected as the candidate compound and enzyme to illustrate the inhibitory kinetics and the mechanism of action.

Kinetics of yGR inhibition

It has been shown that the yGR was inhibited by BITC in a concentration- and time-dependent manner as indicated in Figure 3, which presents a plot derived from the natural logarithm of the GR activity versus time at various concentrations of BITC. The figure shows that the yGR lost activity over time, indicating a characteristic of irreversible enzyme inhibition. By plotting the reciprocal of apparent rate constant of inhibition (k_{app}) (slopes obtained from Figure 3) against the reciprocal of inhibitor concentration, the inhibitory parameters K_i and k_{inact} of BITC were determined to be 259.87 μM and 0.0266 min⁻¹, respectively (Figure 4)²¹.

Confirmation of the irreversible GR inhibition by dialysis

Dialysis of BITC-inhibited yGR was carried out to determine the irreversibility of the GR inhibition by BITC. The BITC-inhibited yGR was extensively dialysed in bulky PE buffer. No GR activity recovery was observed in BITC-inhibited yGR after 24 h-dialysis, thus further confirming the irreversible inhibition of GR by BITC (Figure 5).

Substrate protection assay

The substrate protection assay were conducted in the absence and presence of substrate GSSG to determine whether BITC is a competitive inhibitor of yGR and whether the inhibition occurs at the catalytic centre of GR. It has been shown that GSSG, the substrate of GR, protected yGR from inhibition by BITC in a concentration-dependent manner revealing that the substrate protected the enzyme from inhibition by BITC (Figure 6). The result indicated...
that BITC and GSSG were competing for the same substrate binding site of GR and BITC is a competitive inhibitor of yGR.

**NADPH-dependent GR inhibition**

As a member of the pyridine nucleotide-disulphide oxidoreductase family of homodimeric flavoenzymes, each subunit of GR contains one FAD, two substrate binding sites, and an intramolecular disulphide in oxidised form of GR ($E_{ox}$). During the reductive half-reaction, electrons are transferred rapidly from NADPH on the re side of the flavin to the Cys disulphide on the si side. In the oxidative half-reaction the final electron acceptor GSSG is reduced to 2 GSH, regenerating the disulphide at the active site of GR. So GSSG reduction catalysed by GR, primarily, requires reduction of the disulphide bond at the active site of enzyme to the two-electron-reduced $E_{H_2}$ form by NADPH. GR ($E_{H_2}$) presumably occurs as the principal species of the enzyme in vivo under physiological reducing conditions. To determine whether the Cys residues or the thiol group of Cys residue at the active site are involved in ITCs inhibition, inhibitory experiments in the presence and absence of NADPH were conducted. In Figure 7, inhibition was only observed in the presence of NADPH, indicating that only the reduced thiol(s) in the active site were involved in the inhibition suggesting that it was the GR ($E_{H_2}$) that was inhibited.
Mass spectrometric analysis of BITC-inhibited yGR

yGR was incubated with 0.2 mM BITC in PE buffer in the presence of NADPH for 1 h at room temperature. The BITC-treated and the untreated GR samples were denatured and followed by trypsin digestion. And then the desalted samples were subjected to a Q-Exactive Orbitrap high resolution mass spectrometer equipped with an Easy-nLC 1000 ultra-high pressure nano-HPLC system. The trypsin-digested peptides and their corresponding tandem mass fragment ions of yGR protein sequence (www.uniprot.org; P41921) were predicted by Skyline software (MacCoss Lab, Department of Genome Sciences, University of Washington, USA). The predicted trypsin-digested peptide ALGGTCVNVGCVPK contains the substrate binding sites Cys61 and Cys66. The precursors of unmodified ALGGTCVNVGCVPK, and its corresponding mono-benzyl thiocarbamoylated adduct are m/z 659.3369 [(M + 2H)^+2] and m/z 733.8515 [(M + 2H)^+2], respectively. In the BITC-treated yGR samples, precursor ion at m/z 733.8515 ± 10 ppm (mono-benzyl thiocarbamoylated adduct) rather than m/z 882.8817 (bis-benzyl thiocarbamoylated adduct) was extracted from the mass spectrum (Figure 8(A)) at retention time of 26.16 min indicating that one of the substrate binding sites of yGR was modified by BITC via monomer modification. By investigating the tandem mass of the monomer precursor ion at m/z 733.8515 [(M + 2H)^+2], a series of fragment ions were observed (Table 1, Figure 8(B,C)). A y8 ion (VNVGCVPK) was detected at m/z 815.4444 without BITC modification. A y9 ion which equals the addition of mono-benzyl thiocarbamoylation and the residue CVNVGCVPK, was observed at m/z 1067.4705 revealing that only the thiol on Cys61 was mono-benzyl thiocarbamoylated by BITC (Figure 9). In the same sample, the precursors ion of unmodified ALGGTCVNVGCVPK at m/z 659.3356 [(M + 2H)^+2] was extracted from the mass spectrum (Figure 8(D)) at retention time of 18.90 min. In addition, a series of fragment ions were also observed (Table 1, Figure 8(E)). As in the untreated yGR sample, there was no mono-benzyl thiocarbamoylation detected on Cys61 or Cys66.
**Determination of intracellular GR inhibition in A2780 and A375 cells**

To evaluate whether BITC and PEITC can inhibit intracellular GR, A2780 and A549 cells were treated with BITC or PEITC at 20, 40, 80 and 160 μM concentrations. After a 2 h treatment, the intracellular GR activity was significantly attenuated by BITC or PEITC (Figure 10), indicating that BITC and PEITC can also inhibit intracellular GR activity in the cancer cells.

**Discussions**

BITC and PEITC are two common ITC derivatives derived from glucosinolates and are effective chemo-preventive and anticancer agents against various types of cancer cells. However, the inhibitory effects of ITCs against GR have not been reported. In this study, we have presented that naturally occurring isothiocyanates BITC and PEITC as GR inhibitors are capable of inhibiting purified yGR and intracellular hGR in the human cancer cells. The isothiocyanates own central electrophilic carbons which is able to undergo rapid thiocarbamoylation reactions with cellular thiols. Isothiocyanates react with thiols to generate labile dithiocarbamate adducts. Glutathione, one of the most abundant physiological thiol, is depleted by isothiocyanates through generation of dithiocarbamate adducts. These conjugates can be rapidly effluxed from cells, or metabolised into cysteine–isothiocyanate conjugate which is able to dissociate back to the parent isothiocyanate.

GR inhibitors have been evaluated as potential anticancer and antimalarial agents. BITC and PEITC showed similar inhibitory effects against yGR activity, but PEITC showed lower inhibitory effect against human GR than BITC. Therefore, BITC and yGR were selected as the candidate compound and enzyme to illustrate the inhibitory kinetics and the mechanism of action. BITC exhibited a time- and concentration-dependent inhibitory manner suggesting that the inhibition was irreversible. The irreversible inhibition was further confirmed by the dialysis experiment. When the BITC-inhibited yGR was dialysed extensively, no recovery of enzyme activity was observed. The GR inhibition by BITC was prevented by the presence of substrate GSSG, indicating that most likely the inhibitor was acting at the active site of yGR and competing with the substrate.

All the above evidence indicated the formation of a covalent bond between BITC and the reduced thiol groups at the active site of the enzyme. To identify which residues Cys61 and/or Cys66 are involved in the covalent bond formation with BITC, an LC-MS/MS analysis was performed. Interestingly, the tandem mass spectrometric analysis showed that only the Cys61 residue rather than Cys66 was modified by BITC through a mono-benzyl thiocarbamoyl covalent bond. This finding indicated that BITC inhibits GR by selectively mono-benzyl thiocarbamoylating the thiol at Cys61 residue while the thiol at Cys66 was unaffected (Figure 8). Cys58 and Cys43 are the active sites of hGR, but only Cys58 has been reported highly reactive towards alkylating or benzyl thiocarbamoylation.

**Table 1.** Observed ions of peptide benzyl thiocarbamoylated ALGGTC\*3C3VNVGCVPK and ALGGTC\*3C3VNVGCVPK and their corresponding fragment ions in the tandem mass spectrum of trypsin-digested BITC-treated yeast GR.

| Observed ions | Theoretical (m/z) | Observed (m/z) |
|---------------|------------------|---------------|
| ALGGTC\*3C3VNVGCVPK | 733.8518 (M + 2H) | 733.8515 (M + 2H) |
| ALGGTC\*3C3VNVGCVPK | 659.3369 (M + 2H) | 659.3356 (M + 2H) |
| GGTGVNGVCVPK (y12) | 1133.5447 (M + H) | 1133.5397 (M + H) |
| C\*3VNVGCVPK (y9) | 1067.4840 (M + H) | 1067.4705 (M + H) |
| CVNVGCVPK (y9) | 918.4541 (M + H) | 918.4516 (M + H) |
| VNNGVCVPK (y8) | 815.4449 (M + H) | 815.4444 (M + H) |
| NVGCVPK (y7) | 716.3765 (M + H) | 716.3765 (M + H) |
| GCVPK (y5) | 503.2652 (M + H) | 503.2649 (M + H) |
| PK (y2) | 343.2345 (M + H) | 343.2336 (M + H) |

\*Benzy thiocarbamoylation.

**Figure 9.** Proposed mechanism of yGR inhibition by BITC. The tandem mass analysis of the BITC-inhibited yGR revealed that only the thiol on Cys61 was mono-benzyl thiocarbamoylated by BITC, resulting in irreversible inhibition.

**Figure 10.** Inhibition of intracellular GR by BITC and PEITC in A375 (A) and A2780 (B) cells. A375 and A2780 cells were incubated in the presence of 20, 40, 80 and 160 μM BITC or PEITC for 2 h, and the GR activity was determined and presented as the percentage of the control. The results are shown as the means ± SD of three independent experiments.
carbamoylating agents. BCNU (carmustine), the best known inhibitor of hGR, modified Cys58 of hGR (EH2) instead of hGR (ECO)24. Accordingly, based on our tandem mass spectrometric data, we speculate that the thiol group in Cys46 in yGR is more volatile than Cys66 to be thiocarbamoylated by BITC. The irreversible inhibition of yGR by BITC resembles in part the inhibition of hGR by BCNU. The IC50 of BCNU was reported at 646 μM against GR25, and BITC and PEITC shown much more efficient inhibitory effects against yGR and intracellular GR. Both of BITC and PEITC showed better inhibitory effects against intracellular hGR than purified one, it could be induced by the 100- to 200-fold increased intracellular concentration of ITCs8. GR is a well-known potential target for treatment malarial parasites, in addition, GR-mediated thiol oxidative stress is able to suppress cancer cell metastasis in vitro and in vivo17. It makes ITCs good candidates, most likely lead compounds, for the development of antiparasitic and anticancer drugs.

Conclusions

In summary, we have characterised the irreversible inhibition mechanism of yGR by BITC and PEITC. BITC inhibits yGR by benzyl thio-carbamoylating the thiol group in Cys61 of yGR (EH2). In addition, BITC and PEITC significantly inhibited hGR activity in human melanoma and ovarian cancer cells.

Disclosure statement

The authors confirm that this article’s contents have no conflict of interest.

Funding

This work was supported by the International Cooperation Fund from Science Technology Department of Zhejiang Province (LGJ19H160001); National Natural Science Foundation of China (B1903641&81802995); Zhejiang Provincial Natural Science Foundation of China (LQ18H160016); Medical Science and Technology Project of Zhejiang Province (2018268942).

References

1. Dai MY, Wang Y, Chen C, et al. Phenethyl isothiocyanate induces apoptosis and inhibits cell proliferation and invasion in hep-2 laryngeal cancer cells. Oncol Rep 2016;35:2657–64.
2. Sun M, Shi Y, Dang UJ, Di Pasqua AJ. Phenethyl isothiocyanate and cisplatin co-encapsulated in a liposomal nanoparticle for treatment of non-small cell lung cancer. Molecules 2019;24:801.
3. Brown KK, Hampton MB. Biological targets of isothiocyanates. Biochim Biophys Acta 2011;1810:888–94.
4. Lee CF, Chiang NN, Lu YH, et al. Benzyl isothiocyanate (bitc) triggers mitochondria-mediated apoptotic machinery in human cisplatin-resistant oral cancer cells. Biomedicine (Taipei) 2018;8:15.
5. Lin JF, Tsai TF, Lin YC, et al. Benzyl isothiocyanate suppresses igf1r, fgfr3 and mtor expression by upregulation of mir-99a-5p in human bladder cancer cells. Int J Oncol 2019; 54:2106–16.
6. Xiao D, Bommaraddy A, Kim SH, et al. Benzyl isothiocyanate causes foxo1-mediated autophagic death in human breast cancer cells. PLoS One 2012;7:e32597.
7. Bo P, Lien JC, Chen YY, Yu FS, et al. Allyl isothiocyanate induces cell toxicity by multiple pathways in human breast cancer cells. Am J Chin Med 2016;44:415–37.
8. Gupta P, Kim B, Kim SH, Srivastava SK. Molecular targets of isothiocyanates in cancer: recent advances. Mol Nutr Food Res 2014;58:1685–707.
9. Huang L, Cai C, Dang W, et al. Propyl isothiocyanate induces apoptosis in gastric cancer cells by oxidative stress via glutathione depletion. Oncol Lett 2019;18:5490–8.
10. Trachootham D, Zhou Y, Zhang H, et al. Selective killing of oncogenically transformed cells through a ros-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 2006;10:241–52.
11. Xiao D, Powolny AA, Moura MB, et al. Phenethyl isothiocyanate inhibits oxidative phosphorylation to trigger reactive oxygen species-mediated death of human prostate cancer cells. J Biol Chem 2010;285:26558–69.
12. Xiao D, Lew KL, Zeng Y, et al. Phenethyl isothiocyanate-induced apoptosis in pc-3 human prostate cancer cells is mediated by reactive oxygen species-dependent disruption of the mitochondrial membrane potential. Carcinogenesis 2006;27:2223–34.
13. Deponte M, Urlg S, Arscott LD, et al. Mechanistic studies on a novel, highly potent gold-phosphate inhibitor of human glutathione reductase. J Biol Chem 2005;280:20628–37.
14. Gallwitz H, Bonse S, Martinez-Cruz A, et al. Ajoene is an inhibitor and subversive substrate of human glutathione reductase and trypanosoma cruzi trypanothione reductase: Crystallographic, kinetic, and spectroscopic studies. J Med Chem 1999;42:364–72.
15. Doroshenko N, Doroshenko P. The glutathione reductase inhibitor carmustine induces an influx of ca2+ in pc12 cells. Eur J Pharmacol 2004;497:17–24.
16. Seefeldt T, Zhao Y, Chen W, et al. Characterization of a novel dithiocarbamate glutathione reductase inhibitor and its use as a tool to modulate intracellular glutathione. J Biol Chem 2009;284:2729–37.
17. Li X, Wu J, Zhang X, Chen W. Glutathione reductase-mediated thiol oxidative stress suppresses metastasis of murine melanoma cells. Free Radic Biol Med 2018;129:256–67.
18. Sarma GN, Savvides SN, Becker K, et al. Glutathione reductase of the malarial parasite plasmodium falciparum: Crystal structure and inhibitor development. J Mol Biol 2003;328:893–907.
19. Bohme CC, Arscott LD, Becker K, et al. Kinetic characterization of glutathione reductase from the malarial parasite plasmodium falciparum. Comparison with the human enzyme. J Biol Chem 2000;275:37317–23.
20. Seefeldt T, Dwivedi C, Peitz G, et al. 2-acetylamino-3-[4-(2-acetylamino-2-carboxyethyl)sulfanylcarbonylamino]-phenylcarbamoysulfanyl-propionic acid and its derivatives as a novel class of glutathione reductase inhibitors. J Med Chem 2005;48:5224–31.
21. Kitz R, Wilson IB. Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. J Biol Chem 1962;237:3245–9.
22. Chen W, Jiang Z, Lin N, et al. Evaluation of n-acetyl-s-(p-chlorophenylcarbamoyle)lysine as an irreversible inhibitor of mammalian thioredoxin reductase1. J Enzyme Inhib Med Chem 2016;31:229–35.
23. Syed Alwi SS, Cavell BE, Donlevy A, Packham G. Differential induction of apoptosis in human breast cancer cell lines by phenethyl isothiocyanate, a glutathione depleting agent. Cell Stress Chaperones 2012;17:529–38.

24. Karplus PA, Krauth-Siegel RL, Schirmer RH, Schulz GE. Inhibition of human glutathione reductase by the nitrosourea drugs 1,3-bis(2-chloroethyl)-1-nitrosourea and 1-(2-chloroethyl)-3-(2-hydroxyethyl)-1-nitrosourea. A crystallographic analysis. Eur J Biochem 1988;171:193–8.

25. FitzGerald GB, Bauman C, Hussoin MS, Wick MM. 2,4-dihydroxybenzylamine: A specific inhibitor of glutathione reductase. Biochem Pharmacol 1991;41:185–90.